Biothera is a U.S. biotechnology company dedicated to improving immune health. We manufacture and market patented, natural ingredients for functional foods, beverages and nutritional supplements worldwide. Wellmune WGP® and our other novel yeast beta glucan ingredients are clinically proven to safely prime the immune system to keep your body healthy. Derived from the cell wall of a proprietary strain of baker’s yeast, Wellmune WGP mobilizes billions of innate immune cells that are part of the body’s natural defenses. This unique immune health ingredient helps increase immune cells’ effectiveness without over-stimulating the immune system. Peer-reviewed, published research consistently demonstrates that ability of Wellmune WGP to support protective immune responses during periods of high physical and lifestyle stress. Wellmune WGP’s year-round protection is the culmination of more than $300 million in research with leading university and government institutions. Wellmune is patented, Kosher, Halal, non-allergenic, GMO-free and has broad regulatory approval worldwide, including GRAS in the United States and novel foods approval in the European Union and China. The ingredient is the recipient of a SupplySide West Scientific Excellence Award, an IFT Innovation Award and a Frost & Sullivan Excellence in Research Award.
Key Market Areas/Major Products
Biothera’s flagship ingredient Wellmune WGP® was designed for its primary markets of foods, beverages and premium supplements. The company also markets patented WGP 3-6® for the cosmetic and skin care market and APG 3-6® for the animal nutrition market.
Biothera continues to present and publish new clinical research confirming the safety and efficacy of Wellmune WGP as an immune health ingredient for foods, beverages and supplements. This year, research demonstrating how Wellmune reduced upper respiratory tract infection (URTI) symptoms in fourth-year medical students was published in the journal Nutrition. Clinical research showing how Wellmune increases immune function in athletes was published in the British Journal of Nutrition. And, research demonstrating Wellmune’s ability to reduce URTI symptoms in marathon runners was presented at the American College of Sports Medicine and the National Strength and Conditioning Association annual meetings. Publication is pending and additional research is ongoing at Biothera.
The strength and depth of the body of research underscoring Wellmune supports consumer product claims. This has no doubt been a factor in the number of new products containing Wellmune WGP introduced this year. Nearly 20 new products or line extensions with Wellmune have reached market shelves around the world. Wellmune is now an ingredient in foods, beverages and supplements in more than 50 countries.
Allen Porter, Vice President of Sales
Darryl Mircheff, Vice President of Sales
Dario Herrera, Director of Sales
Published in WholeFoods Magazine, November 2012